GSK has been granted a patent for an implantable neuromodulation system that optimizes neural stimulation parameters based on real-time monitoring of blood-based responses. The system includes a neurostimulator, sensors, and a controller that adjusts stimulation parameters wirelessly to enhance therapeutic outcomes. GlobalData’s report on GSK gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on GSK, Human telomerase RT biomarker was a key innovation area identified from patents. GSK's grant share as of July 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
Implantable neuromodulation system optimizing stimulation via blood parameters
The granted patent US12070604B2 describes a sophisticated neurostimulation system designed to deliver targeted stimulation to nerves or artery/nerve plexuses. The system comprises a neurostimulator that administers stimulation based on an initial set of parameters, alongside one or more sensors that monitor the physiological responses to this stimulation. A key feature of the system is its controller, which adjusts the stimulation parameters according to a titration schedule, ensuring that the stimulation is tailored to the monitored responses. The neurostimulator, sensors, and controller operate within a distributed environment, with at least the neurostimulator and controller communicating wirelessly.
The claims further detail the types of stimulation parameters that can be modified, including amplitude, pulse width, frequency, and waveform shape. The system also emphasizes the importance of monitoring blood-based parameters such as blood flow, blood pressure, and arterial distension, utilizing various sensors like Doppler and impedance sensors. The controller is designed to assess whether the neural stimulation produces a physiological effect and to adjust the stimulation parameters accordingly, particularly if adverse effects on blood-based parameters are detected. This adaptive approach aims to achieve optimal physiological outcomes by ensuring that the stimulation remains effective and safe throughout its application.
To know more about GlobalData’s detailed insights on GSK, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
